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Abstract
Background: Studies have suggested that soluble factors in plasma from patients with active (aBD) and inactive
(iBD) Behçet’s disease (BD) stimulate neutrophil function. Soluble CD40 ligand (sCD40L) is an important mediator of
inflammation in BD. Its expression and effect on neutrophil oxidative burst and neutrophil extracellular trap (NET)
release have not been characterized. In this study, we sought to investigate the role of plasma and the CD40L
pathway on NET release and the oxidative burst profile in patients with aBD and iBD.
Methods: Neutrophils and peripheral blood mononuclear cells (PBMCs) were obtained from patients with aBD (n = 30),
patients with iBD (n= 31), and healthy control subjects (HCs; n = 30). sCD40L plasma concentration was determined in
individual samples. A pool of plasma for each group was created. In some experiments, plasma pools were treated with
recombinant CD40 (rhCD40-muIg) for sCD40L blockade. NET release and H2O2/O2
− production were determined after
stimulation with phorbol 12-myristate 13-acetate, sCD40L, or plasma pool. Flow cytometric analysis was performed to
evaluate the expression of (1) CD40, Mac-1, and phosphorylated NF-κB p65 on neutrophils and monocytes and (2) CD40L
on activated T cells and platelets. CD40L gene expression in PBMCs was determined by qRT-PCR.
Results: sCD40L plasma levels were significantly higher in patients with iBD (median 17,234, range 2346–19,279 pg/ml)
and patients with aBD (median 18,289, range 413–19,883 pg/ml) than in HCs (median 47.5, range 33.7–26.7 pg/ml; p < 0.
001). NET release was constitutively increased in BD compared with HC. NET release and H2O2/O2
− were higher after
stimulation with sCD40L or BD plasma and decreased after sCD40L blockade. Mac-1 expression was constitutively
increased in neutrophils of patients with aBD (88.7 ± 13.2% of cells) and patients with iBD (89.2 ± 20.1% of cells) compared
with HC (27.1 ± 18.8% of cells; p < 0.01). CD40 expression on phagocytes and CD40L expression on platelets were similar
in the three groups. PBMCs as well as nonactivated and activated CD4+ T cells from patients with BD showed higher
CD40L expression.
Conclusions: Plasma from patients with aBD exerts a stimulus on NET release and oxidative burst, probably induced by
sCD40L.
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Background
The pathogenesis of Behçet’s disease (BD) is unknown;
however, there are pieces of evidence pointing to in-
creased neutrophil activation in patients with BD that can
be clinically correlated with the pathergy phenomenon
[1]. Phagocyte functional abnormalities possibly involved
in BD include cytokine production [2], oxidative burst [3],
and phagocytic [4, 5] and microbicidal activity [6], but
divergent results have been reported by different authors
[1, 4, 5, 7, 8]. Our group recently reported on the het-
erogeneity in BD pathophysiology by showing that only
patients with severe active BD exhibit evidence of consti-
tutive neutrophil activation judged on the basis of oxida-
tive burst activity and cytokine production [9].
Although several pieces of evidence point to participa-
tion of neutrophils in BD, evaluation of neutrophil extra-
cellular trap (NET) formation in BD has not been
investigated. Moreover, it is unclear whether phagocyte
activation in patients with BD occurs constitutively,
mainly in those carrying HLA-B51 [3], or if it is second-
ary to an as yet unknown stimulus [10, 11]. Also, has
not been defined whether the neutrophil hyperactive
state is induced by some soluble serum or tissue factor
or if BD neutrophils or other cell subtypes produce sol-
uble inflammatory mediators carried by plasma, as previ-
ously suggested for specific phagocyte functions, such as
chemotaxis [10] and oxidative burst [11].
Soluble CD40 ligand (sCD40L) is a cleaved form of
CD40L present in the plasma. Its membrane-bound
analogue is involved in immunoglobulin isotype switch-
ing, B-cell differentiation, antigen-presenting cell activa-
tion, T-cell modulation, and thrombocyte aggregation
[12]. The major source of sCD40L is activated platelets,
but activated T cells, macrophages, endothelial cells, and
smooth muscle cells also contribute to sCD40L synthesis
and shedding [13].
Fernández-Bello et al. [14] showed higher levels of plasma
and platelet-derived sCD40L in a group of patients with
BD, although no differences in platelet activation or
platelet-leukocyte aggregate formation were observed. In
normal mouse neutrophils, sCD40L strongly stimulates the
oxidative burst via a CD40-dependent phosphoinositide 3-
kinase/NF-κB pathway [15]. Additionally, platelet-derived
sCD40L stimulates expression of the leukocyte-specific β2-
integrin Mac-1 in neutrophils and thereby further promotes
neutrophil adhesion and migration [15]. Therefore, it is
possible that elevated plasma sCD40L contributes to the
characteristic phagocyte hyperactivity in BD.
It has been postulated that BD may be a form of autoin-
flammatory disease [16]. Interestingly, although some
pieces of evidence point to neutrophil hyperactivation in
BD, it is not clear if this is a primary (constitutive)
phenomenon or if it is secondary to putative soluble fac-
tors. We hypothesize that sCD40L carried at increased
levels by the plasma of patients with BD is associated with
systemic phagocyte activation. In the present study, we in-
vestigated the role of plasma from patients with BD and
sCD40L on NET release and oxidative burst profiles in
neutrophils and peripheral blood mononuclear cells
(PBMCs) from patients with active Behçet’s disease (aBD)
and patients with inactive Behçet’s disease (iBD).
Methods
Study subjects and diagnostic criteria
This study included three main subject groups: (1) 30
healthy control subjects (HC), (2) 31 patients with iBD,
and (3) 30 patients with aBD. All patients with BD met
the International Study Group for Behçet’s Disease cri-
teria [17]. Active BD was defined as a score ≥ 2 and iBD
as a score of zero on the Simplified Behçet’s Disease
Current Activity Form adapted for Portuguese by the
Sociedade Brasileira de Reumatologia (sBR-BDCAF)
[18]. The HC group comprised healthy adult volunteers
from the hospital staff with no evidence or family history
of autoimmune disease or immunodeficiency. Addition-
ally, for some experiments, we used samples derived
from 25 patients with sepsis (PSs), 27 patients with in-
active pediatric systemic lupus erythematosus (iSLE),
and 27 patients with active pediatric systemic lupus ery-
thematosus (aSLE). The PS group, a positive control group
for neutrophil activation, consisted of adult inpatients meet-
ing the sepsis criteria of the American College of Chest
Physicians/Society of Critical Care Medicine Consensus
Conference [19]. The SLE group consisted of pediatric pa-
tients meeting the American College of Rheumatology cri-
teria for SLE [20]. Patients scoring ≥ 6 on the Systemic
Lupus Erythematosus Disease Activity Index [21] were con-
sidered to have active disease, and those scoring zero were
considered to have inactive disease. The study was ap-
proved by the institutional ethics review boards of Universi-
dade Federal de São Paulo (CEP 0013/11) and Seattle
Children’s.
Plasma pools
Plasma pools for each group were assembled by mixing
plasma samples derived from heparinized blood drawn
from each subject enrolled in the study. Additionally,
plasma from four different X-linked hyper immuno-
globulin M patients collected at the immunology out-
patient clinic of the University of Sao Paulo was used to
constitute a pool of hyper immunoglobulin M plasma
(HIgM). All pools were stored in aliquots at −80 °C.
RNA extraction and complementary DNA synthesis
RNA was isolated by standard RNA extraction using
TRIzol® Reagent (Life Technologies, Carlsbad, CA,
USA) and transformed into complementary DNA
(cDNA) by using the SuperScript One-Step RT-PCR
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System with Platinum Taq DNA polymerase (Life
Technologies) using a thermocycler (Eppendorf,
Hamburg, Germany).
Quantification of cytokine and soluble receptors in
plasma
After donation, blood samples were immediately spun at
2500 rpm for 15 minutes at room temperature, and 2-ml
plasma aliquots with 40 μl of dipeptidyl peptidase-4 pro-
tease inhibitor (Merck Millipore, Billerica, MA, USA)
were stored at −80 °C. All plasma samples were thawed
only once for determination of the concentration of 13
soluble receptors (HSCR-32 K; Merck Millipore) and 64
cytokines (HCYTOMAG-60 K and HCYP2MAG-62 K;
Merck Millipore) by addressable laser bead immun-
oenzyme assay according to the manufacturer’s specifi-
cations and read using the Luminex MAGPIX® System
40-072 (Merck Millipore). sCD40L plasma levels were
subsequently assessed by enzyme-linked immunosorbent
assay (ELISA) using the Human sCD40L Platinum
ELISA kit (eBioscience, San Diego, CA, USA) according
to the manufacturer’s specifications and read at λ = 450/
570 nm in a VICTOR X3 2030 multilabel ELISA reader
(PerkinElmer, Singapore).
Hydrogen peroxide and superoxide anion quantification
Neutrophils and PBMCs were separated by density gra-
dient separation using dextran and Ficoll-Hypaque 1077,
respectively. Cells were stimulated with (1) 30 ng/ml
phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich,
St. Louis, MO, USA), (2) 50 μl of pooled plasma (from
HCs, patients with iBD, or patients with aBD) with or
without 2 μg/ml recombinant CD40 (rhCD40-muIg;
(R&D Systems, Minneapolis, MN, USA), (3) 50 μl of
pooled plasma from HIgM patients, or (4) 100 ng/ml rh-
sCD40L (Life Technologies). Hydrogen peroxide and
superoxide production was determined by luminol/luci-
genin chemiluminescence intensity and quantified for
2 h at 37 °C during the readout in the VICTOR X3 2030
multilabel plate reader as described previously [22, 23].
Each well was read for 0.5 seconds every 50 seconds,
and the results were expressed as a kinetic curve of rela-
tive light units on the x-axis and time in minutes on the
y-axis. The analysis was based on the AUC.
Expression of nicotinamide adenine dinucleotide
phosphate oxidase components
Gene expression of nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase components was determined
by qRT-PCR as described previously [22]. (Primers are
shown in Additional file 1: Table S1.) Data were acquired
and analyzed using a ViiA 7 RT-PCR system (Thermo
Fisher Scientific, Waltham, MA, USA).
Protein expression of NADPH oxidase subunit protein
expression was determined by flow cytometry. Briefly,
100 μl of whole blood was diluted with 100 μl of PBS
and incubated with 30 ng/ml PMA or 50 μl of pooled
plasma (from HCs, patients with iBD, or patients with
aBD) for 6 h in a 5% CO2 atmosphere at 37 °C. For
gp91-phox and p22 subunit evaluation, the samples were
stained with 2 μl of anti-gp91-phox-fluorescein isothio-
cyanate (Santa Cruz Biotechnology, Dallas, TX, USA)
and 2 μl of anti-p22-phycoerythrin (PE) (Santa Cruz
Biotechnology), respectively, for 30 minutes in the dark.
For p40, p47, and p67 subunit evaluation, the samples
were initially fixed with 50 μl of BD Cytofix fixation buf-
fer (BD Biosciences, San Jose, CA, USA) and then
permeabilized with 50 μl of BD Phosflow Perm Buffer III
(BD Biosciences) according to the manufacturer’s in-
structions. Then, the samples were stained with 2 μl of
anti-p40-AF488 (Santa Cruz Biotechnology), 2 μl of
anti-p47-AF647 (Santa Cruz Biotechnology), and 2 μl of
anti-p67-PE (Santa Cruz Biotechnology). Using a FAC-
SAria III flow cytometer (BD Biosciences), we observed
that monocytes and neutrophils were gated by forward
and side scatter. Acquired data were analyzed using
FlowJo software (FlowJo, Ashland, OR, USA).
Protein expression of NF-κB phosphorylated p65 subunit
Assessment of NF-κB p65 subunit phosphorylation was
performed by flow cytometry as previously described
[24] following incubation with 30 ng/ml PMA or 50 μl
of pooled plasma (from HCs, patients with iBD, or pa-
tients with aBD) for 15 minutes in a 5% CO2 atmosphere
at 37 °C.
NET formation
NET release was determined as previously described
[25] after stimulation with 30 ng/ml PMA, 100 ng/ml
rh-sCD40L, or 50 μl of pooled plasma (from HCs,
patients with iBD, or patients with aBD) with or
without 2 μg/ml rhCD40-muIg. Cells were stained
with primary anti-histone H2A/B (kindly provided by
Dr. Arturo Zychlinsky, Max Planck Institute, Berlin,
Germany) and anti-human neutrophil elastase mono-
clonal antibodies (Abcam, Cambridge, UK). Bisbenzi-
mide (Life Technologies) was used for DNA labeling.
Three random microscopic fields (×400 magnification)
were photographed with a × 40 or × 63 lens objective
and 17, 20, and 21 high-efficiency filters for each
fluorochrome, respectively. Total NET area in each
photo was calculated using ZEN lite 2012 (black
edition) software (Carl Zeiss, Oberkochen, Germany).
CD40L protein and gene expression
CD40L protein expression was determined by flow cy-
tometry as previously described [14, 26]. Platelets were
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obtained and assessed by flow cytometry for CD40L pro-
tein expression before and after stimulation with 0.2 U/
ml thrombin for 5 minutes at 37 °C in a 5% CO2 atmos-
phere [14]. CD40L protein expression in monocytes and
in CD4+ and CD8+ T lymphocytes was determined by
flow cytometry before and after stimulation with 1.5 μM
ionomycin (Sigma-Aldrich) and/or 25 ng/ml PMA [26].
CD40L gene expression in PBMCs was determined be-
fore and after stimulation with 10 ng/ml PMA for 3 h
using the TaqMan® Gene Expression qRT-PCR Assay for
CD40L (Thermo Fisher Scientific). cDNA levels were
normalized to the expression of glyceraldehyde 3-
phosphate dehydrogenase (Thermo Fisher Scientific).
Statistical analysis
Continuous variables were evaluated using the
Kolmogorov-Smirnov test and analyzed using Student’s t
test (normal distribution) or the Mann-Whitney U test
(nonparametric distribution). Qualitative parameters were
analyzed using the chi-square test and Fisher’s exact test
when appropriate. Multiparametric analyses were con-
ducted with one-way analysis of variance (ANOVA)
followed by Bonferroni posttests when appropriate. The
statistical inference level was set at 0.05.
Results
Study subject characteristics
The female-to-male ratios were 14:16 in the aBD group
and 15:16 in the iBD group, with ages ranging from 20
to 57 years (36.13 ± 11.02) and from 20 to 55 years
(40.96 ± 9.72), respectively. The female-to-male ratios
were 18:12 in the HC group, 14:11 in the PS group, 18:9
in the iSLE group, and 22:5 in the aSLE group, with age
ranges varying from 24 to 62 years (35.63 ± 9.49), 20 to
82 years (46.00 ± 25.76), 6 to 18 years (14.32 ± 2.96), and
7 to 20 years (15.12 ± 3.48), respectively. The HIgM
plasma pool was constituted of plasma from four X-
linked hyper-IgM male patients aged 4, 5, 7, and 8 years.
Patients with BD and control subjects did not differ re-
garding gender distribution. The HC, iBD, aBD, and PS
groups did not differ regarding age distribution. The
iSLE, aSLE, and HIgM groups were significantly younger
than the other groups.
Miscellaneous comorbidities (osteoarthritis, osteope-
nia/osteoporosis, glaucoma, arterial hypertension, dyslip-
idemia, chronic obstructive pulmonary disease, and
epilepsy, among others) were equally present in patients
with iBD (n = 22; 70.96%) and patients with aBD (n = 19;
63.33%) (p = 0.59). The clinical characteristics and thera-
peutic regimens of patients with BD are shown in
Table 1. There were no significant differences between
patients with aBD and patients with iBD regarding previ-
ous disease manifestations. All patients were under
treatment at the time of the study. As expected, the
number of patients with aBD receiving cyclophospha-
mide or high doses of corticosteroids was higher than
among patients with iBD.
NET release is increased by neutrophils from patients
with BD and is further stimulated by plasma from
patients with BD
Neutrophils from patients with BD showed a higher rate
of spontaneous NET release than those from HCs, al-
though no difference was observed after stimulation with
PMA (Fig. 1a). When stimulated with plasma, neutro-
phils from patients with BD released more NET than
HCs’ neutrophils (Fig. 1b). Moreover, NET release was
more strongly stimulated by plasma from patients with
aBD than by plasma from HCs or patients with iBD
(Fig. 1c). Figure 2 shows photomicrographs illustrating
the results.
Plasma from patients with BD stimulates oxidative burst
and NADPH oxidase protein expression
Superoxide and hydrogen peroxide production in resting
phagocytes was similar in patients with BD and HCs.
Plasma from patients with BD, but not from HCs, stimu-
lated oxidative burst in phagocytes from normal individ-
uals and patients with BD (Fig. 3a–d). Interestingly,
neutrophils from HCs produced more superoxide
(Fig. 3a) and hydrogen peroxide (Fig. 3b) after stimula-
tion with aBD plasma than with iBD and HC plasma. In
general, PMA stimulated higher superoxide production
in neutrophils than any other stimulus; however, hydro-
gen peroxide production by aBD neutrophils was higher
after aBD plasma than after PMA stimuli, and hydrogen
peroxide production by iBD neutrophils after PMA
stimulation was equivalent to that observed with iBD or
aBD plasma stimuli.
Similar results were also observed in PBMC assays, in
which superoxide (Fig. 3c) and hydrogen peroxide pro-
duction (Fig. 3d) were higher after BD plasma stimula-
tion than after HC plasma stimulation. Remarkably, aBD
plasma exerted a stronger effect than iBD plasma on
superoxide production by PBMCs from HCs and were
even comparable to PMA on aBD cells (Fig. 3c). In all
the other comparisons, reactive oxygen species produc-
tion by PMA-stimulated PBMCs was higher than with
any other stimulus.
To determine whether the increased production of re-
active oxygen species by BD neutrophils could be a re-
sult of increased expression of the NADPH oxidase
subunits, we evaluated the level of subunit expression by
both messenger RNA (mRNA) and protein analysis. Ex-
pression of each NADPH oxidase subunit gene was
equivalent in resting neutrophils (Fig. 4a) and PBMCs
(Fig. 4b) from HCs, patients with iBD, and patients with
aBD. Cells from a group of 25 patients with severe sepsis
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were used as a positive control and, as expected, exhib-
ited higher expression of gp91-phox, p22, p40, and p67
NADPH oxidase subunits. As for NADPH oxidase pro-
tein, the expression of the five subunits in neutrophils
and monocytes increased significantly after stimulation
with aBD or iBD plasma. Interestingly, plasma from HCs
also caused an increase in NADPH oxidase protein
expression, but plasma from patients with BD had a sig-
nificantly stronger effect (Table 2).
CD40/CD40L pathway is associated with increased NET
release and oxidative burst in patients with BD
The above results indicate a possible soluble factor car-
ried by the plasma from patients with BD that would be
Table 1 Distribution of patients with inactive and active Behçet’s disease, according to clinical manifestations and medication use
iBD (n = 31) (%) aBD (n = 30) (%)
Current Previous Current Previous
Clinical manifestations
Oral ulcers 0 31 (100) 21 (70.0) 30 (100)
Genital ulcers 0 28 (90.3) 5 (16.7) 24 (80.0)
Anterior uveitis 0 14 (45.2) 11 (36.7) 8 (26.7)
Posterior uveitis 0 10 (32.3) 7 (23.3) 11 (36.7)
Other ocular manifestationsa 0 5 (16.1) 4 (13.3) 5 (16.7)
Pseudofolliculitis 0 18 (58.1) 6 (20.0) 11 (36.7)
Erythema nodosum 0 15 (48.4) 8 (26.7) 14 (46.7)
CNS 0 7 (22.6) 5 (16.7) 5 (16.7)
Gastrointestinal 0 2 (6.5) 0 1 (3.3)
Cardiovascular 0 5 (16.1) 3 (10.0) 4 (13.3)
Pathergy 5 (16.1) 2 (6.7)
Othersb 0 13 (41.9) 5 (16.7) 9 (30.0)
Disease duration, years, median/minimum–maximum 9/1 – 30 6/0 – 19
Age at BD onset, years, mean (SD) 30.1 ± 9.6 28.7 ± 12.0
sBR-BDCAF, median/minimum–maximum 0/0 – 0 3/2 – 4
Medications 26 (83.9) 29 (93.5) 28 (93.3) 23 (76.7)
Colchicine 14 (45.2) 11 (35.5) 15 (50.0) 5 (16.7)
Azathioprine 14 (45.2) 10 (32.5) 16 (53.3) 4 (13.3)
Thalidomide 2 (6.5) 7 (22.6) 3 (10.0) 3 (10.0)
Methotrexate 3 (9.7) 6 (19.4) 1 (3.3) 3 (10.0)
Cyclophosphamide 0* 7 (22.6) 5 (16.7)c 2 (6.7)
Penicillin G benzathine 4 (12.9) 7 (22.6) 4 (13.3) 4 (13.3)
Anti-TNF 5 (16.1) 0 1 (3.3) 1 (3.3)
Corticosteroids
High dose 5 (16.1)d 13 (41.9) 15 (50.0)d 12 (40.0)
Low dose 5 (16.1) 18 (58.1) 6 (20.0) 10 (33.3)
Cyclosporine 1 (3.2) 6 (19.4) 6 (20.0) 5 (16.7)
Pentoxifylline 2 (6.5) 2 (6.5) 1 (3.3) 2 (6.7)
Minocycline 0 3 (9.7) 0 0
Dapsone 0 0 0 1 (3.3)
Chlorambucil 0 2 (6.5) 0 1 (3.3)
Sulfasalazine 0 1 (3.2) 0 0
Abbreviations: aBD Active Behçet’s disease, BD Behçet’s disease, CNS Central nervous system, iBD Inactive Behçet’s disease, sBR-BDCAF Simplified Behçet’s Disease
Current Activity Form adapted for Portuguese by the Sociedade Brasileira de Reumatologia, TNF Tumor necrosis factor
aIncluded cases with optic neuritis, vitreous hemorrhage, sudden blindness, and so forth
bOther manifestations: BD-induced dementia, arthralgia/arthritis, folliculitis decalvans, and so forth
cp < 0.05
dp < 0.01
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responsible for activating NET release and oxidative
burst. In an effort to identify this factor, we determined
the concentration of 64 cytokines and 13 soluble recep-
tors in the plasma from patients with BD and from HCs
by multiplex technology (Additional file 2: Table S2).
Among the several factors that showed the greatest dif-
ferences between HC and BD plasma, sCD40L was
markedly higher in samples from patients with BD
(Fig. 5a). This result was confirmed by ELISA, which
demonstrated that sCD40L plasma levels from patients
with aBD are significantly higher than those from HCs
and patients with iBD (Fig. 5b). To gauge the compara-
tive level of CD40L expression in patients with BD, we
quantified sCD40L in patients with iSLE and patients with
aSLE, whose CD40L expression is known to be highly up-
regulated in CD4+ T cells and even aberrantly expressed
on CD8+ T cells, B cells, and monocytes [27, 28]. Despite
sCD40L levels being markedly elevated in aSLE, the levels
observed in aBD were even higher. In patients with iBD,
sCD40L plasma levels were comparable to those in
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Fig. 1 Neutrophil extracellular trap (NET) release is increased in Behçet’s disease (BD). a Resting neutrophils from healthy control subjects (HCs; n = 6),
patients with active Behçet’s disease (aBD; n = 6), patients with inactive Behçet’s disease (iBD; n = 6), patients without stimulus, and after phorbol 12-
myristate 13-acetate stimulation. b Effect of plasma from HCs, patients with iBD, and patients with aBD on NET release by neutrophils from HCs and
patients with BD. (c) Plasma from patients with aBD exerted a stronger stimulus on NET formation by neutrophils from HC and patients with BD. Bars
represent mean ± SE. Statistical analysis was performed with one-way analysis of variance and the Bonferroni posttest
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patients with aSLE and higher than those in HCs and pa-
tients with iSLE (Fig. 5b). It is remarkable that patients
with aBD presented a wide range of sCD40L plasma levels,
suggesting some heterogeneity in the pathophysiology of
the disease. Of note, nonautoimmune diseases previously
associated with high levels of sCD40L, such as myocardial
infarction [29], atherosclerosis [30], and diabetes mellitus
[31], were not observed in our cohort. Furthermore, the
distribution of other risk factors for cardiovascular dis-
eases, namely arterial hypertension (iBD = 9.67% vs aBD =
20%; p = 0.3) and dyslipidemia (iBD = 22.58% vs aBD =
6.66%; p = 0.14), was not different between the two groups
of patients.
We then investigated the hypothesis that sCD40L was
the stimulating factor responsible for the increased
NETosis and oxidative burst after stimulation with BD
plasma. In in vitro experiments, we stimulated cells with
recombinant sCD40L or with plasma from patients with
BD in the presence or absence of rhCD40-muIg used as
a specific sCD40L blocking agent. NET release was sig-
nificantly reduced after sequestering sCD40L with
rhCD40-muIg and increased when stimulated with re-
combinant sCD40L (Fig. 5c). Similarly, superoxide
(Fig. 5d and f) and hydrogen peroxide (Fig. 5e and g)
production by neutrophils (Fig. 5d and e) and PBMCs
(Fig. 5f and g) from patients with iBD, patients with
aBD, and HCs was also significantly stimulated by
sCD40L and decreased by sCD40L blockade. In addition,
sCD40L-poor plasma obtained from patients with
CD40L deficiency (hyper-IgM plasma) was not able to
increase oxidative burst (Fig. 5d–g).
CD40L, Mac-1, and phosphorylated NF-κB p65 subunit are
overexpressed in patients with BD
To determine the source of the elevated sCD40L in the
plasma of patients with BD, we evaluated expression by
the normal cell sources of CD40L in peripheral blood.
Although platelets are a major source of sCD40L, no dif-
ference in CD40L protein expression was observed in
platelets from patients with BD compared with those of
HCs (Fig. 6a). In contrast, on one hand, CD40L gene ex-
pression was strikingly increased in resting PBMCs from
patients with BD compared with HCs, but there was not
an additional increase after PMA stimulation (Fig. 6b).
On the other hand, the number of CD4+CD40L+ T cells
from patients with BD was significantly higher after
combined PMA-ionomycin stimulation, suggesting that
there is a larger preexisting pool of CD40L protein in T
cells (Fig. 6c). Interestingly, contrary to previous obser-
vations in patients with lupus [27, 28], CD40L expres-
sion on CD8+ T cells and monocytes from patients with
BD was not different from that observed in HC cells
(Additional file 3: Figure S1). Additionally, macrophage
integrin Mac-1, but not CD40 protein, was overex-
pressed in resting neutrophils (Fig. 6d) and monocytes
(Fig. 6e) from patients with BD compared with those
Fig. 2 Neutrophil extracellular trap (NET) release stimulated by phorbol 12-myristate 13-acetate (PMA) or by a pool of plasma from healthy control
subjects (HCs), patients with inactive Behçet’s disease (iBD), and patients with active Behçet’s disease (aBD). Immunofluorescence photomicroscopy
illustrates the effect of plasma from patients with Behçet’s disease (BD) in normal and BD neutrophils. White bars indicate scale = 50 μm; green= histone
H2A/B; red = human neutrophil elastase; blue= chromatin
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from HCs. Finally, phosphorylation of the NF-κB p65
subunit was constitutively increased in neutrophils and
monocytes from patients with BD, suggesting chronic
baseline activation (Fig. 6f ) of these cells. Importantly,
phosphorylation of the NF-κB p65 subunit was signifi-
cantly increased in normal neutrophils and monocytes
after stimulation with iBD or aBD plasma (Fig. 6g).
Discussion
In this study, we systematically evaluated several phago-
cyte functions in BD, thus complementing previous in-
vestigations in which researchers assessed individual
neutrophil functions in this disease [4, 8, 10, 32]. Previ-
ous findings demonstrating the absence of primary acti-
vation of BD phagocytes [9] and the stimulating effect of
plasma from patients with BD on chemotactic function
[10] and oxidative burst [11] of normal neutrophils cor-
roborate our findings that a soluble plasma factor plays
a relevant role in the neutrophil hyperactivity observed
in BD, which is the main contribution of the present
study. NET release by neutrophils, but not the oxidative
burst of phagocytes, was increased in nonstimulated
cells from patients with BD. Stimulation with BD plasma
induced a significant increase in both functions, in some
instances comparable to a PMA-induced response. Inter-
estingly, neutrophils from patients with aBD exhibited
higher hydrogen peroxide production after stimulation
with aBD plasma than other cells or stimuli, suggesting
that cells from patients with active disease are in a “pre-
activated” state.
Several of the evaluated soluble mediators were in-
creased in plasma from patients with BD in comparison to
that from HCs; however, the elevation in sCD40L plasma
levels in patients with BD was striking. Remarkably, aBD
plasma exerted a stronger stimulus on NET release than
iBD or HC plasma, correlating with the higher levels of
sCD40L in aBD vs iBD. Moreover, the recapitulation of
the stimulating effect of BD plasma on phagocyte function
by treatment with rh-sCD40L and the inhibition by
sCD40L blockade further support our interpretation that
sCD40L carried in BD plasma is directly associated with
some of the functional abnormalities observed in BD
phagocytes. This was further supported by our demonstra-
tion that sCD40L-deficient plasma failed to stimulate
hydrogen peroxide or superoxide production in similar
experiments.
Fig. 3 Plasma from patients with Behçet’s disease (BD) stimulates phagocyte oxidative burst activity. Superoxide (a and c) and hydrogen peroxide
(b and d) production by neutrophils (a and b) and peripheral blood mononuclear cells (PBMCs) (c and d) from healthy control subjects (HCs; n =
30), patients with active Behçet’s disease (aBD; n = 30), and patients with inactive Behçet’s disease (iBD; n = 31) after human plasma or phorbol 12-
myristate 13-acetate stimuli, calculated by the AUC. In general, BD plasma exerted a strong stimulus to oxidative burst by phagocytes from HCs,
patients with iBD, and patients with aBD. Bars represent mean ± SE. Statistical analysis was performed by one-way analysis of variance with the
Bonferroni posttest
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High sCD40L serum levels have been demonstrated in
other rheumatic autoimmune diseases [33–36], espe-
cially in SLE [37]. By comparing the relative amount of
sCD40L present in BD with that in SLE, we found
sCD40L plasma levels in aSLE to be comparable to those
observed in iBD and significantly lower than those ob-
served in patients with aBD, highlighting the significant
background activation of this pathway in BD. Notably, the
level of sCD40L expression in patients with iSLE was simi-
lar to that observed in HCs. Our data confirm and extend
previous findings by demonstrating, in BD cells, the
stimulating effect of sCD40L on NET release and oxi-
dative burst and by providing evidence suggesting that this
effect is initiated by NF-κB signaling, as previously
described in mice [14, 38]. Mac-1 may be secondarily in-
volved in this phenomenon because this adhesion receptor
complex, usually upregulated on activated myeloid cells, is
overexpressed in resting BD neutrophils [15].
Platelets are the main source of sCD40L, but other
cells can express and shed CD40L, including activated T
cells. In contrast to the study by Fernández-Bello et al.
[14], our study did not show abnormally high CD40L ex-
pression by activated platelets from patients with BD;
differences in methodology may be the reason for this
discrepancy. We used a physiologic stimulus (thrombin
activation), whereas Fernández-Bello et al. [14] used a
synthetic thrombin receptor-activating peptide assay. In
contrast to our observations in platelets, we clearly dem-
onstrate increased CD40L surface expression by in vitro
activated CD4+ T cells associated with increased basal
gene expression by PBMCs from patients with BD.
Therefore, our hypothesis is that CD4+ T cells from pa-
tients with BD constitutively present an enlarged pool of
mRNA and preformed CD40L protein, which in turn is
quickly expressed at the membrane surface under stress.
Ultimately, activated T cells may also contribute to the
Fig. 4 Gene expression of the five nicotinamide adenine dinucleotide phosphate (NADPH) oxidase subunits (gp-91-phox, p22, p40, p47, and p67)
in resting neutrophils (a) and peripheral blood mononuclear cells (PBMCs) (b) from healthy control subjects (HCs; n = 30), patients with sepsis
(PSs; n = 25), patients with inactive Behçet’s disease (iBD; n = 31), and patients with active Behçet’s disease patients (aBD; n = 30). Statistical analysis
was performed using the Kruskal-Wallis test with the Mann-Whitney posttest
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Table 2 Nicotinamide adenine dinucleotide phosphate oxidase subunit protein expression in neutrophils and monocytes
Cell
source
Stimulus
None PMA HC plasma iBD plasma aBD plasma
Neutrophils
gp91-phox
HC 23.98 ± 11.55 399.71 ± 47.86a 148.26 ± 29.29 261.27 ± 32.52b 271.33 ± 44.23b
iBD 19.66 ± 11.23 402.00 ± 71.57a 156.95 ± 31.23 291.87 ± 45.39b 297.35 ± 22.48b
aBD 32.68 ± 17.61 464.71 ± 48.45a 139.05 ± 32.75 277.88 ± 41.76b 278.64 ± 39.95b
p22
HC 20.93 ± 11.40 453.04 ± 70.51a 139.25 ± 31.37 262.56 ± 36.43b 281.02 ± 53.86b
iBD 23.72 ± 12.25 438.87 ± 52.98a 132.62 ± 17.28 279.12 ± 38.67b 282.62 ± 35.75b
aBD 38.82 ± 24.88 422.75 ± 64.76a 152.78 ± 9.32 288.74 ± 30.77b 314.94 ± 40.60b
p40
HC 22.73 ± 9.96 377.33 ± 115.38a 165.77 ± 33.20 279.88 ± 38.13b 299.00 ± 49.97b
iBD 42.43 ± 7.36 453.37 ± 77.82a 133.37 ± 16.08 279.00 ± 50.57b 293.12 ± 31.47b
aBD 28.85 ± 12.85 475.42 ± 79.97a 160.71 ± 20.86 274.71 ± 55.96b 253.00 ± 36.56b
p47
HC 22.16 ± 9.23 383.05 ± 69.88a 132.90 ± 38.84 247.97 ± 92.38b 280.63 ± 59.20b
iBD 35.68 ± 22.66 447.75 ± 41.11a 151.53 ± 29.26 274.12 ± 50.08b 270.12 ± 56.07b
aBD 21.04 ± 7.94 400.00 ± 57.01a 141.27 ± 34.16 282.12 ± 16.01b 293.00 ± 50.48b
p67
HC 32.78 ± 13.00 487.36 ± 93.67a 162.11 ± 32.10 288.44 ± 42.48b 296.11 ± 55.36b
iBD 36.61 ± 15.39 396.50 ± 57.82a 145.12 ± 30.69 289.50 ± 46.72b 266.12 ± 54.21b
aBD 26.42 ± 9.91 425.42 ± 50.71a 160.00 ± 22.37 296.71 ± 42.42b 274.57 ± 39.45b
Monocytes
gp91-phox
HC 29.75 ± 16.20 412.02 ± 68.52a 154.13 ± 19.00 355.05 ± 107.18b 421.50 ± 78.28b
iBD 16.43 ± 5.38 415.43 ± 60.54a 148.00 ± 33.64 318.06 ± 17.94b 330.40 ± 15.98b
aBD 22.41 ± 8.09 468.62 ± 30.17a 149.41 ± 26.47 263.51 ± 50.51b 282.71 ± 50.99b
p22
HC 21.37 ± 12.57 486.14 ± 82.35a 157.44 ± 40.22 267.42 ± 34.51b 281.82 ± 39.82b
iBD 23.00 ± 14.07 442.61 ± 44.55a 157.41 ± 30.28 281.65 ± 35.56b 283.66 ± 43.68b
aBD 27.25 ± 21.68 414.80 ± 33.12a 129.20 ± 15.01 272.47 ± 29.72b 235.70 ± 53.94b
p40
HC 28.21 ± 10.94 467.00 ± 67.57a 147.22 ± 25.00 286.11 ± 37.36b 273.77 ± 53.97b
iBD 54.53 ± 6.55 560.12 ± 74.73a 142.25 ± 30.90 259.25 ± 42.82b 289.25 ± 35.70b
aBD 45.62 ± 9.24 468.75 ± 78.34a 137.00 ± 25.80 290.37 ± 31.87b 301.25 ± 44.61b
p47
HC 27.45 ± 11.87 387.52 ± 45.42a 155.84 ± 17.92 246.52 ± 37.54b 263.57 ± 60.32b
iBD 23.56 ± 15.99 416.77 ± 49.75a 118.50 ± 27.70 278.71 ± 35.03b 286.70 ± 49.01b
aBD 29.49 ± 23.42 427.37 ± 63.68a 160.71 ± 24.88 264.12 ± 21.63b 262.01 ± 38.54b
p67
HC 27.09 ± 17.14 453.77 ± 62.69a 160.44 ± 27.99 272.55 ± 42.45b 275.22 ± 46.01b
iBD 29.01 ± 12.42 420.12 ± 71.30a 140.37 ± 26.73 281.75 ± 38.49b 303.75 ± 48.17b
aBD 29.41 ± 12.61 447.00 ± 67.93a 142.50 ± 34.80 249.75 ± 39.07b 269.50 ± 33.04b
Abbreviations: aBD Active Behçet’s disease, HC Healthy control, iBD Inactive Behçet’s disease, PMA Phorbol 12-myristate 13-acetate
Neutrophils and monocytes were obtained from HCs (n = 9), patients with iBD (n = 8), and patients with aBD (n = 8), and protein expression as determined by
mean fluorescence intensity was found to be increased after stimulation with BD plasma
Statistical analysis was performed using one-way analysis of variance with the Bonferroni posttest
a p < 0.05 compared with unstimulated cells and any other stimulus
b p < 0.05 compared with unstimulated cells and stimulation with plasma from HCs
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high sCD40L plasma levels observed in BD. In addition,
because BD is primarily a mucocutaneous disorder,
fibroblast and epithelial cells, especially those from the
uvea, retina, and oral and genital cavities, are also candi-
dates to be sources of sCD40L. Further studies are ne-
cessary to test this hypothesis.
The finding that resting phagocytes from patients with
BD and HCs did not differ regarding oxidative profile
and NADPH oxidase gene and protein expression sup-
ports the concept that phagocyte dysfunction in BD is
not constitutional. By the same token, our results pro-
vide hints about the origin of the factors stimulating
phagocytes in BD, because NADPH oxidase expression
and oxidative burst activity increased after stimulation
with the BD plasma pools. Interestingly, though, sCD40L
blocking inhibited superoxide and hydrogen peroxide
production less intensely in neutrophils than in PBMCs,
suggesting the presence of additional stimulatory serum
factors acting on neutrophils. Although the main con-
tribution of the present study relies on showing the
original association between sCD40L and phagocyte
function in BD, other soluble mediators were slightly but
significantly increased in patients with BD, and several
others are yet to be described. Moreover, each cell type
has distinct responsiveness to different stimuli, which
can also explain the differences observed between neu-
trophils and PBMCs. Additional studies are already be-
ing designed by our group in an effort to clarify this
question.
Increased NET release has previously been demon-
strated in SLE [39], rheumatoid arthritis [40], and anti-
neutrophil cytoplasmic antibody-associated vasculitis
[41]. Our study demonstrates increased NET release by
resting neutrophils from patients with BD and a further
increase after stimulation with aBD plasma, indicating
that circulating neutrophils from these patients have
Fig. 5 Soluble CD40 ligand (sCD40L) plasma levels are increased in patients with Behçet’s disease (BD) and stimulate neutrophil extracellular trap
(NET) release and oxidative burst. a Screening with the addressable laser bead immunoassay (see Additional file 2: Table S2 for more details)
showed strikingly higher sCD40L plasma levels in patients with inactive Behçet’s disease (iBD; n = 31) and patients with active Behçet’s disease
(aBD; n = 30) than in healthy control subjects (HC; n = 30). b sCD40L plasma levels measured by enzyme-linked immunosorbent assay in HCs,
patients with iBD, patients with aBD, and patients with active systemic lupus erythematosus (aSLE; n = 27) or patients with inactive systemic lupus
erythematosus (iSLE; n = 27). c Effect of sCD40L or plasma from HCs, patients with iBD, and patients with aBD blocked with recombinant human
CD40 (rhCD40-muIg) upon NET release by neutrophils from HCs and patients with BD. d–g Superoxide (d and f) and hydrogen peroxide (e and
g) production by neutrophils (d and e) and peripheral blood mononuclear cells (PBMCs) (f and g) after stimulation with sCD40L, CD40L-poor
plasma from hyper immunoglobulin M (hyper-IgM) patients, or aBD plasma containing sCD40L-blocking rhCD40-muIg, calculated by the AUC.
Bars are defined as follows: a Median; b–g mean ± SE. Statistical analysis was performed using the Kruskal-Wallis test with the Mann-Whitney
posttest (a) or one-way analysis of variance with the Bonferroni posttest (b–g)
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undergone some degree of activation. We hypothesize
that the proinflammatory environment in BD, especially
represented by elevated sCD40L plasma levels, sti-
mulates neutrophil activation and NET release in vivo.
Recent studies suggest that NETosis also serves as a
physical trail directing cell migration, especially of
phagocytes, to inflammatory sites [42]. In view of the
current demonstration of increased NETosis in BD, we
hypothesize that this mechanism contributes to the in-
creased neutrophil migration [8] and chemotaxis [10]
observed in this disease. Further studies should address
possible signaling pathways involved in sCD40L-induced
NET release and phagocyte migration in BD.
The evidence provided here opens potential opportun-
ities for the development of targeted therapies. A study in
a lupus mouse model [43] and a phase I clinical study
using a PEGylated anti-CD40L antibody fragment showed
promising results [44]. However, previous clinical trials
done to determine the efficacy of anti-CD40L therapy in
transplantation [45] and immune thrombocytopenic
purpura [46] were discontinued because of severe
thromboembolic events probably caused by cross-linking
of CD40L on platelets.
Interleukin (IL)-8 is a chemoattractant and neutrophil
activator and thus would be a candidate plasma factor
involved in the phagocyte activation observed in BD.
This possibility is favored by pieces of evidence, includ-
ing increased IL8 gene expression in macrophages after
stimulation with aBD plasma [47] as well as high IL-8
serum [48] and synovial concentrations in patients with
BD [49]. Surprisingly, our data did not demonstrate in-
creased IL-8 plasma levels in patients with BD, which
may be related to the wide genotypic and phenotypic
variation that may occur in distinct ethnic groups, sug-
gesting that various factors associated with sCD40L may
be acting in the disease’s pathogenesis. Additionally, the
Fig. 6 CD40 ligand (CD40L) gene expression is increased in peripheral blood mononuclear cells (PBMCs) from patients with Behçet’s disease (BD).
a Platelet expression of CD40L (mean fluorescence intensity [MFI]) was determined under basal conditions and after 5 minutes with 0.2 IU/ml
thrombin by flow cytometry in healthy control subjects (HCs), patients with inactive Behçet’s disease (iBD), and patients with active Behçet’s disease
(aBD). b Higher CD40L relative gene expression in PBMCs from patients with BD than in HCs was demonstrated by qRT-PCR, despite an inability to
increase CD40L expression in BD cells after 3 h of stimulation with 10 ng/ml phorbol 12-myristate 13-acetate (PMA). c A higher number of CD4+CD40L
+ T cells from patients with BD than from HCs after 3-h stimulation with 25 ng/ml PMA + 1.5 μM ionomycin, determined by flow cytometry. d and e
The number of Mac-1+ neutrophils was constitutively increased in patients with BD (d) and monocytes (e), determined by flow cytometry.
No difference in CD40 surface expression was observed. f Phosphorylated NF-κB p65 subunit expression in resting neutrophils and monocytes
from patients with BD was significantly higher than in HCs. g Plasma from patients with BD exerted a stronger stimulus on phosphorylated NF-κB p65
subunit expression than HC plasma in normal neutrophils and monocytes. Bars represent mean ± SE. Statistical analysis was performed using one-way
analysis of variance with the Bonferroni posttest
Perazzio et al. Arthritis Research & Therapy  (2017) 19:235 Page 12 of 15
multiplex screening method used may not detect small
differences between the groups, constituting an inde-
pendent bias.
As a pleiotropic and polygenic disease, patient hetero-
geneity is an important bias. Although clinical and thera-
peutic confounding variables did not demonstrate any
interference with the parameters studied, such factors
can never be completely ruled out. It should be noted
that colchicine, a medication previously demonstrated to
inhibit inflammasome activation [50], NF-κB activation
[51], and superoxide production [52], had been equally
administered in the iBD and aBD groups. Moreover, our
cohort was constituted of a sample of the Brazilian
population, which represents a unique blend of Euro-
pean, African, and Native American descendants. There-
fore, our findings should be confirmed in studies of
other ethnic groups exposed to distinct environmental
conditions because our patients may represent only a
fraction of the cases and a piece in the BD pathophysio-
logic enigma.
Conclusions
The present study shows that plasma from patients with
BD exerted a strong stimulus on the production of react-
ive oxygen species and NET release, and it provides evi-
dence indicating that this effect is induced by sCD40L.
In addition, it provides evidence that resting neutrophils
from patients with BD display increased NET-releasing
activity. These preliminary results suggest new possibil-
ities for further exploring the role of the CD40/CD40L
pathway in phagocyte functional abnormalities in BD
pathophysiology, and they may suggest novel therapeutic
targets for this disease.
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